Beyond Air’s (XAIR) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Beyond Air (NASDAQ:XAIR) in a research report released on Friday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

A number of other analysts have also recently commented on the company. Weiss Ratings restated a “sell (e)” rating on shares of Beyond Air in a research report on Monday, December 22nd. Wall Street Zen raised Beyond Air to a “sell” rating in a research report on Saturday, March 7th. Finally, Rodman & Renshaw started coverage on Beyond Air in a research note on Tuesday, January 20th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Beyond Air presently has an average rating of “Hold” and an average target price of $10.00.

Beyond Air Price Performance

XAIR opened at $0.72 on Friday. The firm’s 50 day simple moving average is $1.05 and its two-hundred day simple moving average is $1.45. The company has a market capitalization of $7.61 million, a PE ratio of -0.13 and a beta of 0.41. Beyond Air has a 1-year low of $0.67 and a 1-year high of $5.84. The company has a current ratio of 5.12, a quick ratio of 4.77 and a debt-to-equity ratio of 2.65.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings data on Friday, February 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.31). The business had revenue of $2.19 million for the quarter, compared to the consensus estimate of $2.15 million. Beyond Air had a negative net margin of 447.75% and a negative return on equity of 268.82%. As a group, equities analysts forecast that Beyond Air will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Beyond Air

Institutional investors have recently bought and sold shares of the business. Alpine Global Management LLC bought a new position in shares of Beyond Air in the third quarter worth about $25,000. Geode Capital Management LLC raised its stake in Beyond Air by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock valued at $144,000 after purchasing an additional 12,598 shares during the period. Virtu Financial LLC bought a new stake in Beyond Air during the 3rd quarter valued at approximately $48,000. Osaic Holdings Inc. lifted its holdings in Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Beyond Air in the 3rd quarter worth approximately $1,753,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.